Annette Langer-Gould to Disease Progression
This is a "connection" page, showing publications Annette Langer-Gould has written about Disease Progression.
Connection Strength
2.012
-
De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy. Mult Scler. 2026 Apr; 32(4):409-420.
Score: 0.879
-
Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies. Neurol Neuroimmunol Neuroinflamm. 2021 03; 8(2).
Score: 0.617
-
Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis. Neurology. 2026 Jan 27; 106(2):e214473.
Score: 0.216
-
Race, ethnicity, and cognition in persons newly diagnosed with multiple sclerosis. Neurology. 2020 04 07; 94(14):e1548-e1556.
Score: 0.145
-
The incidence of clinically isolated syndrome in a multi-ethnic cohort. J Neurol. 2014 Jul; 261(7):1349-55.
Score: 0.096
-
Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol. 2006 Dec; 63(12):1686-91.
Score: 0.058